Julie R. Brahmer, MD
Immunotherapy advances in the treatment paradigm for patients with metastatic non–small cell lung cancer (NSCLC) could eventually lead to a cure for this disease, said Julie R. Brahmer, MD.
State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Brahmer provided an overview of the landscape of metastatic NSCLC, specifically addressing the combination immunotherapy studies with the greatest impact.
OncLive: What do we know about immunotherapy in stage IV disease?
: When looking at a patient with metastatic NSCLC, we first look at what type of histology they have–nonsquamous versus squamous–driver mutations they may have, specifically whether or not they have EGFR
or PD-L1 status. Immunotherapy may or may not be an option for most patients with driver mutations, specifically EGFR
. The first-line clinical trials did not include these patients. Right now, therapies such as tyrosine kinase inhibitors (TKIs) are recommended for first-line treatment of these patients.
... to read the full story